Abstract 167P
Background
Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer and is accompanied by frequent primary or acquired resistance to first-line treatment of chemo-immunotherapy resulting in very modest clinical benefit. Lurbinectedin is FDA-approved as a second-line treatment for SCLC.
Methods
In this study, we evaluated the effect of lurbinectedin on the immune microenvironment in SCLC in multiple immunocompetent mouse models and performed multi-color flow cytometry and bulk RNA sequencing.
Results
In multiple immunocompetent SCLC mouse models, lurbinectedin treatment remarkably enhanced the anti-tumor effect of PD-L1 blockade in tumors that show primary resistance to immunotherapy. Moreover, lurbinectedin caused significant tumor regression in mice that had developed acquired resistance to chemoimmunotherapy treatment demonstrating its efficacy as a superior second-line treatment. Lurbinectedin treatment caused micronuclei formation and activated the cGAS/STING pathway, induced the expression of Type I and II interferon pathways, and caused significant tumor infiltration of cytotoxic and memory/effector T-cells. Similarly, pro-inflammatory M1 type macrophages and dendritic cells were increased, while immunosuppressive M2 type macrophages and MDSC cells were dramatically decreased. Interestingly, lurbinectedin also led to significant induction of MHC class I in SCLC in vitro and in vivo models. Analysis of pre-and post-treatment clinical samples in patients with relapsed SCLCs validated the induction of MHC class I and interferon pathway genes. Finally, pre-and post-lurbinectedin treatment demonstrated a STING-mediated increase in damage-associated molecular patterns (DAMPs) associated with immunogenic cell death.
Conclusions
We provide the first mechanistic insight into the lurbinectedin-induced cGAS-STING activation and multimodal immune modulation in SCLC. Lurbinectedin is already approved as a second-line agent in SCLC. Hence, our findings highlight lurbinectedin as a potentially transformative therapy for SCLCs that have relapsed from chemoimmunotherapy treatment, paving the way for combination clinical trials with anti-PD-L1.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
78P - Final Analysis of the French Real-World Study EVIDENS: Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display